In the past two years, foundational AI models for structural biology have made important technical progress. Despite these advances, current models still show limited accuracy in areas that are central to drug discovery.
The AI Structural Biology (AISB) Network - a collective of large biopharmaceutical companies and Apheris as a federation technology provider - was formed to address these barriers.
In this case study we explore:
- The challenges around access to high-quality molecular data for Life Sciences
- How the Network consisting of major pharmaceutical companies, prestigious model building partners and Apheris as the technology provider was created to tackle this
- Dive into an example initiative: Fine-tuning OpenFold3 on public pharma data to improve accuracy and generalizability